Press release
Retinitis Pigmentosa Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Retinitis Pigmentosa Pipeline. Dive into DelveInsight's comprehensive report today! @ Retinitis Pigmentosa Pipeline Outlook [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Retinitis Pigmentosa Pipeline Drugs Assessment Report
* In May 2025, Neurotech Pharmaceuticals announced a study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II & III, and Choroideremia. This research is being done because there are no effective therapies for people with these retinal degenerations. They are genetic disorders that affect one's ability to see at night, and later cause tunnel vision and loss of central vision. Retinal degenerations affect the retina, a light sensitive layer of cells in the back of the eye. Slowly over time, these cells die and cause permanent loss of vision.
* In May 2025, Beacon Therapeutics conducted a study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
* In May 2025, AAVantgarde Bio Srl organized 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
* DelveInsight's Retinitis Pigmentosa Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Retinitis Pigmentosa treatment.
* The leading Retinitis Pigmentosa Companies such as MeiraGTx, Aldeyra Therapeutics, Inc., SparingVision, Frontera Therapeutics, ProQR Therapeutics, Bionic Sight, RetroSense Therapeutics, Dompe Farmaceutici, Endogena Therapeutics, Nacuity Pharmaceuticals, Kiora Pharmaceuticals, jCyte, Ocugen, Neurotech USA, Nanoscope Therapeutics and others.
* Promising Retinitis Pigmentosa Pipeline Therapies such as Setmelanotide, PBI-4050, OpCT-001, QR-421a, NPI-001, QR-1123, AAVB-081 and others.
Stay ahead with the most recent pipeline outlook for Retinitis Pigmentosa. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Retinitis Pigmentosa Treatment Drugs [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Retinitis Pigmentosa Emerging Drugs Profile
* Botaretigene sparoparvovec : MeiraGTx
Botaretigene sparoparvovec (bota-vec) is designed to treat the most common form of X-linked retinitis pigmentosa (XLRP) caused by mutations in the eye-specific form of the RPGR gene called RPGR open reading frame 15 (RPGR ORF15). Both rods and cones photoreceptors require RPGR ORF15 to function. AAV-RPGR has received Fast Track and Orphan Drug designations from the FDA, as well as PRIME, ATMP and Orphan Medicinal Product designations from the EMA. Currently, the drug is in Phase III stage of its development for the treatment of renitis pigmentosa.
* ADX-2191: Aldeyra Therapeutics, Inc.
ADX-2191 is a novel drug candidate being developed by Aldeyra Therapeutics, Inc. The drug candidate is tetrahydrofolate dehydrogenase inhibitors and thymidylate synthase inhibitors. ADX-2191 received orphan drug designation in 2018. Currently, the drug is in Phase II stage of its development for the treatment of renitis pigmentosa.
* SPVN-06 : SparingVision
SPVN06, is a novel product candidate that acts independently of the causative gene mutation. SPVN06 counteracts the degeneration of cone photoreceptors by restoring RdCVF, a neurotrophic factor naturally produced by functioning rods in the retina; and by promoting RdCVFL, a potent antioxidant which protects cones against oxidative stress. The DNA of the two distinct isoforms (RdCVF and RdCVFL) of the NXNL1 gene are supplied via an Adeno-associated virus (AAV), a viral vector classically used in gene therapy. SPVN06 is delivered via the subretinal route to the cones and retinal pigmented epithelium (RPE). Upon delivery of SPVN06, the transgenes are mainly expressed in the RPE cells for RdCVF and in the cones for RdCVFL. SPVN06 is expected to provide a long-lasting neuroprotective effect to prevent the progression of RP in patients with moderate to severe pathology. Currently, the drug is in Phase I/II stage of its development for the treatment of renitis pigmentosa.
* FT-002: Frontera Therapeutics
FT-002 is a recombinant adeno-associated virus gene therapy drug intended to treat patients with X-linked retinitis pigmentosa (XLRP) caused by RPGR gene mutation. There is no treatment for this disease globally. FT-002 is an intraocular injection of recombinant AAV virus carrying the gene that expresses active functional proteins and repairs damaged retinal cell structure and function. One injection can effectively delay disease progression or restore the patient's visual function. FT-002 is the first AAV gene therapy drug to be tested in XLRP patients in China and is also a potential first-in-class drug. Currently, the drug is in Phase I/II stage of its development for the treatment of Renitis Pigmentosa.
The Retinitis Pigmentosa Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Retinitis Pigmentosa with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinitis Pigmentosa Treatment.
* Retinitis Pigmentosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Retinitis Pigmentosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinitis Pigmentosa market
Explore groundbreaking therapies and clinical trials in the Retinitis Pigmentosa Pipeline. Access DelveInsight's detailed report now! @ New Retinitis Pigmentosa Drugs [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Retinitis Pigmentosa Companies
MeiraGTx, Aldeyra Therapeutics, Inc., SparingVision, Frontera Therapeutics, ProQR Therapeutics, Bionic Sight, RetroSense Therapeutics, Dompe Farmaceutici, Endogena Therapeutics, Nacuity Pharmaceuticals, Kiora Pharmaceuticals, jCyte, Ocugen, Neurotech USA, Nanoscope Therapeutics and others.
Retinitis pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Retinitis Pigmentosa Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Retinitis Pigmentosa Treatment. Learn about new Retinitis Pigmentosa Pipeline Drugs Assessment Developments, and key companies with DelveInsight's expert analysis @ Retinitis Pigmentosa Market Drivers and Barriers [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Retinitis Pigmentosa Pipeline Report
* Coverage- Global
* Retinitis Pigmentosa Companies- MeiraGTx, Aldeyra Therapeutics, Inc., SparingVision, Frontera Therapeutics, ProQR Therapeutics, Bionic Sight, RetroSense Therapeutics, Dompe Farmaceutici, Endogena Therapeutics, Nacuity Pharmaceuticals, Kiora Pharmaceuticals, jCyte, Ocugen, Neurotech USA, Nanoscope Therapeutics and others.
* Retinitis Pigmentosa Pipeline Therapies- Setmelanotide, PBI-4050, OpCT-001, QR-421a, NPI-001, QR-1123, AAVB-081 and others.
* Retinitis Pigmentosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Retinitis Pigmentosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Retinitis Pigmentosa Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Retinitis Pigmentosa Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Retinitis Pigmentosa: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Retinitis Pigmentosa- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Botaretigene sparoparvovec : MeiraGTx
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ADX-2191: Aldeyra Therapeutics, Inc.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* SPVN-06 : SparingVision
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Retinitis Pigmentosa Key Companies
* Retinitis Pigmentosa Key Products
* Retinitis Pigmentosa- Unmet Needs
* Retinitis Pigmentosa- Market Drivers and Barriers
* Retinitis Pigmentosa- Future Perspectives and Conclusion
* Retinitis Pigmentosa Analyst Views
* Retinitis Pigmentosa Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=retinitis-pigmentosa-pipeline-appears-robust-with-40-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/retinitis-pigmentosa-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Retinitis Pigmentosa Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4024319 • Views: …
More Releases from ABNewswire
Hillman Unveils New-Generation Hunting Boots for Men Featuring Dual-Insulation a …
Image: https://www.abnewswire.com/upload/2025/09/ba5edccf338bc4d7305201efbc60a77a.jpg
Hillman, the performance hunting brand trusted by professionals across rugged North American terrain, today announced the release of its next-generation line of hunting boots for men [https://hillmangear.com/collections/hunting-boots-men-s-hunt-footwear], engineered with a dual-insulation system inspired by space technology. The new hunting boots collection features NASA-developed Aerogel Trademark paired with Matrix Registered insulation to deliver arctic-level warmth at a fraction of the weight and bulk of traditional padded boots.
Purpose-built for early season…
Cedric D. Fisher & Company Publishers Releases SIGHT: Groundbreaking Novel Explo …
Cedric D. Fisher & Company Publishers launches SIGHT by Alexandria Clarimond, a literary fiction novel following Elora ("Ellie") through seven decades of life as she confronts progressive blindness from macular degeneration. The novel's innovative "Seven Sight Loss Events" structure parallels physical vision decline with spiritual awakening, creating a powerful meditation on resilience and meaning.
SAN ANTONIO, TX - September 18th, 2025 - Cedric D. Fisher & Company Publishers, a San Antonio-based…
New Launch Protech Systems - A Security System Installation Company in Vancouver …
Protech Systems, a newly launched security system installation company in Vancouver, BC, is now open to serve homeowners and businesses. The company specializes in installing and integrating advanced security solutions, including alarm systems, security cameras, smart home integrations, and monitoring services.
Vancouver, BC - Protech Systems has officially launched in Vancouver, British Columbia, bringing modern home and commercial security solutions to families and business owners across the Lower Mainland. With over…
Soft Tissue Sarcoma Market to Experience Notable Growth in Forecast Span by 2034 …
The Key Soft Tissue Sarcoma Companies in the market include - Epizyme, Blueprint Medicines, Eli Lilly, Philogen, Intensity Therapeutics, Peel Therapeutics, Pure Biologics, Edgewood Oncology, Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, and others.
The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.…
More Releases for Retinitis
Shaping the Retinitis Pigmentosa Market in 2025: Innovative Gene Therapy Develop …
How Big Is the Retinitis Pigmentosa Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, a significant expansion has been witnessed in the market size of retinitis pigmentosa. The market is set to rise from $11.32 billion in 2024 to $12.22 billion in 2025, delivering a compound annual growth rate (CAGR) of 8.0%. The proliferation in the preceding period is due to progress in genetic…
Shaping the Retinitis Pigmentosa Market in 2025: Innovative Gene Therapy Develop …
How Big Is the Retinitis Pigmentosa Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, a significant expansion has been witnessed in the market size of retinitis pigmentosa. The market is set to rise from $11.32 billion in 2024 to $12.22 billion in 2025, delivering a compound annual growth rate (CAGR) of 8.0%. The proliferation in the preceding period is due to progress in genetic…
Retinitis Pigmentosa Market Growth and Treatment Advancements
The retinitis pigmentosa (RP) market has garnered considerable attention in recent years due to its profound impact on individuals' lives. As one of the leading causes of hereditary blindness, RP is a genetic eye disorder that progressively leads to vision loss. The market for retinitis pigmentosa treatments was valued at USD 14.02 billion in 2023, and with significant advancements on the horizon, it is expected to reach USD 21.40 billion…
Retinitis Pigmentosa Market Research and Market Share Insights
The Business Research Company recently released a comprehensive report on the Global Retinitis Pigmentosa Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
Cytomegalovirus Retinitis Market Forecast 2031: Growth and Opportunities
The "Cytomegalovirus Retinitis Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Retinitis Pigmentosa (Retinitis) Market Analysis and Future Prospects for 2030
The world of the retinitis pigmentosa (retinitis) market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing…
